{"DataElement":{"publicId":"3028740","version":"1","preferredName":"Past 12 Month Recreational Drug Use Name","preferredDefinition":"Text term to identify a recreational drugs (cocaine, heroin, methamphetamine, ecstasy) used by a person in the past 12 month.","longName":"PAST_12M_REC_DRG_NM","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3028730","version":"1","preferredName":"Past 12 Month Recreational Drug Use","preferredDefinition":"Before the present time._A number with no fractional part.::12_One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks._A drug used for personal enjoyment rather than for medicinal purposes._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.","longName":"PAST_12M_REC_DRG_USE","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3028728","version":"1","preferredName":"Past Integer::12 Month Recreational Drug","preferredDefinition":"Past; before the present time.:A number with no fractional part.::12:One of the 12 divisions of a year as determined by a calendar.  It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.:A drug used for personal enjoyment rather than for medicinal purposes.","longName":"C25609:C45255::12:C29846:C8436","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Past","conceptCode":"C25609","definition":"Before the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Month","conceptCode":"C29846","definition":"One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recreational Drug","conceptCode":"C84368","definition":"A drug used for personal enjoyment rather than for medicinal purposes.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DBF7-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2234899","version":"1","preferredName":"Use","preferredDefinition":"Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose.","longName":"C25340","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Use","conceptCode":"C25340","definition":"A manner, or usual, or accepted practice of using something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-7486-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-15","modifiedBy":"ONEDATA","dateModified":"2005-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008566","version":"1","preferredName":"Behavior","preferredDefinition":"Observations and activities relating to behavior, such as smoking and ETOH use.\r\n","longName":"BEHAVIOR","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B78145CC-5DBF-209B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-25","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-25","modifiedBy":"REEVESD","dateModified":"2004-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DC05-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3028734","version":"1","preferredName":"Recreational Drug Name","preferredDefinition":"A drug used for personal enjoyment rather than for medicinal purposes._The words or language units by which a thing is known.","longName":"REC_DRG_NM","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"36","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Heroin","valueDescription":"Heroin","ValueMeaning":{"publicId":"2728917","version":"1","preferredName":"Heroin","longName":"2728917","preferredDefinition":"A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diacetylmorphine","conceptCode":"C424","definition":"A narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46014B32-C270-3FE8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8265E3B6-DC82-FF0B-E040-BB89AD4332A6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"Cocaine","valueDescription":"Cocaine","ValueMeaning":{"publicId":"2958779","version":"1","preferredName":"Cocaine","longName":"2958779v1.00","preferredDefinition":"A tropane alkaloid with central nervous systems (CNS) stimulating and local anesthetic activity. Cocaine binds to the dopamine, serotonin, and norepinephrine transport proteins and inhibits the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. This leads to an accumulation of the respective neurotransmitters in the synaptic cleft and may result in increased postsynaptic receptor activation. The mechanism of action through which cocaine exerts its local anesthetic effects is by binding to and blocking the voltage-gated sodium channels in the neuronal cell membrane. By stabilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cocaine","conceptCode":"C80153","definition":"A tropane alkaloid with central nervous systems (CNS) stimulating and local anesthetic activity. Cocaine binds to the dopamine, serotonin, and norepinephrine transport proteins and inhibits the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. This leads to an accumulation of the respective neurotransmitters in the synaptic cleft and may result in increased postsynaptic receptor activation. The mechanism of action through which cocaine exerts its local anesthetic effects is by binding to and blocking the voltage-gated sodium channels in the neuronal cell membrane. By stabilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77BBF6DE-EB22-A1B9-E040-BB89AD437D1C","latestVersionIndicator":"Yes","beginDate":"2009-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-11-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8265E3B6-DC8C-FF0B-E040-BB89AD4332A6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"3,4-Methylenedioxymethamphetamine","valueDescription":"3,4-Methylenedioxymethamphetamine","ValueMeaning":{"publicId":"3028736","version":"1","preferredName":"3,4-Methylenedioxymethamphetamine","longName":"3028736","preferredDefinition":"A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic, neurotoxic, and motor-stimulatory activities. 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"3,4-Methylenedioxymethamphetamine","conceptCode":"C61081","definition":"A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic, neurotoxic, and motor-stimulatory activities. 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DC99-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8265E3B6-DCB2-FF0B-E040-BB89AD4332A6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"},{"value":"Methamphetamine","valueDescription":"Methamphetamine","ValueMeaning":{"publicId":"3028738","version":"1","preferredName":"Methamphetamine","longName":"3028738v1.00","preferredDefinition":"An amphetamine with central nervous system (CNS) stimulating activity. Methamphetamine acts by both facilitating the release of catecholamines, particularly noradrenaline, dopamine and serotonin, from nerve terminals in the brain and by inhibiting their uptake. This leads to an increase in synaptic concentration of these neurotransmitters and results in increased stimulation of postsynaptic receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methamphetamine","conceptCode":"C61840","definition":"An amphetamine with central nervous system (CNS) stimulating activity. Methamphetamine acts by both facilitating the release of catecholamines, particularly noradrenaline, dopamine and serotonin, from nerve terminals in the brain and by inhibiting their uptake. This leads to an increase in synaptic concentration of these neurotransmitters and results in increased stimulation of postsynaptic receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DCBF-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8265E3B6-DCD8-FF0B-E040-BB89AD4332A6","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008566","version":"1","preferredName":"Behavior","preferredDefinition":"Observations and activities relating to behavior, such as smoking and ETOH use.\r\n","longName":"BEHAVIOR","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B78145CC-5DBF-209B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-25","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-25","modifiedBy":"REEVESD","dateModified":"2004-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3028733","version":"1","preferredName":"Recreational Drug Name","preferredDefinition":"A drug used for personal enjoyment rather than for medicinal purposes.:The words or language units by which a thing is known.","longName":"C84368:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recreational Drug","conceptCode":"C84368","definition":"A drug used for personal enjoyment rather than for medicinal purposes.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DC5E-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"ONEDATA","dateModified":"2010-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DC6F-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":"2023.9.1 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812727","version":"1","longName":"U of Pa Cancer Center","context":"NCIP"},{"publicId":"2812868","version":"1","longName":"U Pa Cancer Center New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What drugs","type":"Preferred Question Text","description":"What drugs","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8265E3B6-DD08-FF0B-E040-BB89AD4332A6","latestVersionIndicator":"Yes","beginDate":"2010-03-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-22","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":"Curated for U of Pennsylvania Oncofertility study.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}